Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good
Am J Respir Crit Care Med
.
2024 Aug 1;210(3):367-368.
doi: 10.1164/rccm.202402-0337LE.
Authors
Susanne Stowasser
1
,
Gregory P Cosgrove
2
,
Eric S White
3
Affiliations
1
Boehringer Ingelheim International GmbH & Company, Ingelheim, Germany.
2
Pliant Therapeutics, Inc., South San Francisco, California; and.
3
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.
PMID:
38820300
PMCID:
PMC11348970
DOI:
10.1164/rccm.202402-0337LE
No abstract available
Publication types
Letter
Comment
MeSH terms
Aged
Female
Humans
Idiopathic Pulmonary Fibrosis* / physiopathology
Male
Middle Aged
Quality of Life